QView Medical maintains leadership position in AI-powered breast cancer screening technology through alliance with GE Healthcare
Haryana Blog/10164834
Trending...
- UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
- Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
- Smith Strong Merges With Gravis Law, Bringing Gravis Law to Virginia
LOS ALTOS, Calif. - HaryanaBlog -- QView Medical, a breast cancer detection pioneer and maker of the FDA-approved artificial intelligence (AI) software system for breast cancer screening, and GE Healthcare today announced that QView's QVCAD software can be launched on GE Healthcare's Invenia™ ABUS 2.0 (Automated Breast Ultrasound), which has an open platform technology that allows the integration of third-party AI tools for the optimization of the reading workflow.
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence.
Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%1, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection2.
Mammography misses one third of cancers in dense breasts3, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates4. Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care6.
More on Haryana Blog
"ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.
Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts. The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence. Identifying breast cancer at the earliest possible stage has important prognostic implications: a greater number of available treatment options, increased survival rates and an improved quality of life."
QView supports the #AMIDENSE public health effort to raise awareness of breast density as a major risk factor.
About QView Medical, Inc.
QView Medical develops and sells AI image-analysis systems for the reading of 3D Automated Breast Ultrasound Systems (ABUS) The QView team has been the leader AI technologies for over twenty-five years including the development of R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS and QView AI/QVCAD. QView is located in Los Altos, California. Visit our website www.qviewmedical.com for more information.
More on Haryana Blog
--
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. The powerful AI Assistant leverages intelligent algorithms to assist in detecting breast lesions, helping physicians increase their reading speed with confidence.
Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%1, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection2.
Mammography misses one third of cancers in dense breasts3, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates4. Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care6.
More on Haryana Blog
- Education Through Music-LA Honors Grammy-Winning Pitch Perfect Music Supervisors Julianne Jordan & Julia Michels, Educator Anthony "Tony" White
- TOKSTAR Welcomes NBA 2K Star Young Wayne
- Matt Zavala of Zavala Law, PC Elected to Ventura County Bar Association Board of Directors
- Montana Artist Ryan Jolley Receives Goodman Award at Mountain Oyster Club Art Show
- Make Your Move to Luxury Living at Heritage at Hopewell with Rates Starting at Just 3.750% (5.803% APR)
"ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.
Brian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts. The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence. Identifying breast cancer at the earliest possible stage has important prognostic implications: a greater number of available treatment options, increased survival rates and an improved quality of life."
QView supports the #AMIDENSE public health effort to raise awareness of breast density as a major risk factor.
About QView Medical, Inc.
QView Medical develops and sells AI image-analysis systems for the reading of 3D Automated Breast Ultrasound Systems (ABUS) The QView team has been the leader AI technologies for over twenty-five years including the development of R2 mammography CAD, R2 lung CT CAD, U-Systems ABUS and QView AI/QVCAD. QView is located in Los Altos, California. Visit our website www.qviewmedical.com for more information.
More on Haryana Blog
- Scott Glickson Joins STS Capital Partners as Managing Director
- BREAKTHROUGH TROP2 Research Reveals New REQORSA® Opportunities as Roche Collaboration Strengthens Precision Lung Cancer Strategy
- Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Dallas–Fort Worth
- PinnacleQM launches new enterprise website to help Australian organisations deliver more with confidence
- Loud! OOH Launches UK's First Free Planning Tool for UK Outdoor Advertising Budgets
--
- Interpretation Time Using a Concurrent-Read Computer-Aided Detection System for Automated Breast Ultrasound in Breast Cancer Screening of Women With Dense Breast Tissue (Yulei Jiang). Read More: https://www.ajronline.org/doi/10.2214/AJR.18.19516
- Performance and Reading Time of Automated Breast US with or without Computer-aided Detection. Read More: https://pubs.rsna.org/doi/10.1148/radiol.2019181816
- Pisano et al. Diagnostic Performance of Digital versus Film Mammography
- Mandelson et al. Journal Natl Cancer Inst 2000; 92:1081–1087 for Breast –Cancer Screening. NEJM 2005; 353:1773
- Boyd, et al, NEJM Jan 2007
- Blumen, et al. Comparison of treatment costs for breast cancer by tumor stage and type of service
Contact
Robert M. Foley
Vice President, Marketing
QView Medical, Inc. 1-844-643-9527
info@qviewmedical.com
Robert M. Foley
Vice President, Marketing
QView Medical, Inc. 1-844-643-9527
info@qviewmedical.com
Source: QView Medical, Inc
0 Comments
Latest on Haryana Blog
- Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
- Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
- Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
- Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
- Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
- The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
- LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
- Security Planning Tips For Your Holiday Event From Access Patrol Services
- Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
- Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
- Kitchen Table Economics: An Invitation to Think Differently
- Win a $5,000 VIP Family Experience at the 100th Thanksgiving Day Parade in New York City
- CB Stuffer Announces Private Sale to Secure Future of Brand Growth
- The Fifth Annual "Bamboo Lantern Festival" to Illuminate Tokyo Mizumachi and Sumida River Walk®
- Iglesia.com Positioned in Multimillion-Dollar Domain Market with $10 Million Asking Price
- TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
- Searching for the Next LBE Creator: CalArts Launches First-Ever D.R.E.A.M.S. Pitch Competition
- Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
- Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
- ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
